31-01-2013 дата публикации
Номер: US20130028900A1
The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof. 1. An isolated conformation-specific antibody or fragment thereof that specifically binds to a Xaa-Pro motif of a polypeptide , wherein the peptidyl-prolyl bond of said Xaa-Pro motif is in a cis conformation or a trans conformation and wherein Xaa is any amino acid residue.2. The isolated antibody of claim 1 , wherein said Xaa is serine or threonine.3. The isolated antibody of claim 1 , wherein said Xaa is phosphorylated.4. The isolated antibody of claim 1 , wherein said Xaa is not phosphorylated.5. The isolated antibody of claim 1 , wherein said antibody or fragment thereof binds to the cis conformation of said Xaa-Pro motif of said polypeptide with at least 10- to 100-fold greater affinity than to the trans conformation of said Xaa-Pro motif of said polypeptide.6. The isolated antibody of claim 1 , wherein said antibody or fragment thereof binds to the trans conformation of said Xaa-Pro motif of said polypeptide with at least 10- to 100-fold greater affinity than to the cis conformation of said Xaa-Pro motif of said polypeptide.7. The isolated antibody of claim 1 , wherein said polypeptide is a PPIase substrate.8. The isolated antibody of claim 7 , wherein said PPIase substrate is a Pin1 substrate.9. The isolated antibody of claim 8 , wherein said Pin1 substrate is NIMA claim 8 , RAB4 claim 8 , CDC25 claim 8 , WEE1 claim 8 , PLK1 claim 8 , MYT1 claim 8 , CDC27 claim 8 , CENP-F claim 8 , Incenp claim 8 , RBP1 claim 8 , NHERF-1 claim 8 , KRMP1 claim 8 , CK2 claim 8 , TopoIIα claim 8 , DAB2 claim 8 , p54nrb claim 8 , Sil claim 8 , EMI1 claim 8 , cyclin D1 claim 8 , Ki67 claim 8 , c-Myc claim 8 , cyclin E claim 8 , c-Jun claim 8 , β-catenin claim 8 , Cf-2 claim 8 , NF-κB claim 8 , RAF1 claim 8 , c-Fos claim 8 , RARα claim 8 , AIB1/SRC-3 claim 8 , HBx claim 8 , STAT3 claim 8 , p53 claim 8 , BcI-2 claim 8 , p73 claim 8 , BimEL ...
Подробнее